Chris Boerner, Bristol Myers Squibb CEO (Tierney L. Cross/Bloomberg via Getty Images)

Bris­tol My­ers touts long-term ef­fi­ca­cy of re­cent­ly ac­quired Karuna drug

Fresh off clos­ing its $14 bil­lion ac­qui­si­tion of Karuna Ther­a­peu­tics a few weeks ago, Bris­tol My­ers Squibb is pre­sent­ing long-term da­ta for its new sub­sidiary’s promis­ing schiz­o­phre­nia drug, known as KarXT.

Bris­tol My­ers said KarXT’s ef­fi­ca­cy was main­tained through one year in an open-la­bel ex­ten­sion, pre­sent­ing the da­ta Sat­ur­day at the Schiz­o­phre­nia In­ter­na­tion­al Re­search So­ci­ety con­gress. Ad­di­tion­al­ly, more than 75% of pa­tients who con­tin­ued tak­ing the drug for a year achieved a “clin­i­cal­ly mean­ing­ful” re­sult, BMS se­nior VP of glob­al drug de­vel­op­ment Roland Chen told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.